Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Elizabeth McCusker"'
Autor:
Akshay Swaminathan, Jeremy Snider, Jeffrey M. Venstrom, Rebecca A. Miksad, Siraj M. Ali, Brian M. Alexander, Alexa B. Schrock, Margaret Elizabeth McCusker, Stacey Stein, Emily Castellanos, Russell Madison
Publikováno v:
Future Oncology. 17:4101-4114
Aim: To assess concordance between HER2 status measured by traditional methods and ERBB2 amplification measured by next-generation sequencing and its association with first-line trastuzumab clinical benefit in patients with advanced esophagogastric c
Autor:
Teresa Srajer, Francisco Cardoso, Ralf Reilmann, Asuncion Martinez, Julie C. Stout, Elizabeth McCusker, Claudia M. Testa, Zhong Pei, Bernhard Landwehrmeyer, Christopher A. Ross, Jamie Levey, Blair R. Leavitt, Sarah J. Tabrizi, Jee Bang
Publikováno v:
Movement Disorders Clinical Practice
Autor:
Emilia Gatto, Elizabeth McCusker, Martin Cesarini, José Luis Etcheverry, Javier Enrique Ziliani, Gustavo Da Prat, Natalia González Rojas
Publikováno v:
Journal of Huntington's Disease. 8:195-198
Background Huntington's disease (HD) is a neurodegenerative disorder that includes motor, psychiatric and cognitive manifestations with typical onset of symptoms is in the forties. A percentage of patients (4.4% - 11.5%) may be exceptions to this and
Autor:
Elizabeth McCusker, Clement T. Loy
Publikováno v:
Neurology. 96:875-876
The motor manifestations of Huntington disease (HD) cause a severe burden, but it is often the nonmotor impairments of behavior and cognition that have the greatest impact early in the disease course, sometimes even before motor symptoms or signs are
Autor:
Raymond A. Martin, Joseph S. Kass, Steven Warach, Richard Payne, Kathleen M. Foley, Raja Mehanna, Elizabeth McCusker, Stephen J. Victor, Joseph C. Masdeu, Allen J. Aksamit, Alan C. Carver, Michael P. McQuillen
Publikováno v:
Neurology.
In legal physician-hastened death, a physician prescribes medication with the primary intent of causing the death of a willing terminally ill patient. This practice differs radically from palliative sedation, intended to relieve a patient's suffering
Autor:
Jeremy Snider, Stella Stergiopoulos, Cheryl D. Cho-Phan, Akshay Swaminathan, Margaret Elizabeth McCusker, Emily Castellanos, Leah Comment, Rachel Cunningham, Virginia Fisher, Tamara Snow
Publikováno v:
Cancer Research. 81:864-864
Background: Four-fold growth in the past decade of actionable molecular targets for aNSCLC makes comprehensive assessment of pts' alteration status increasingly important. NGS can concurrently detect multiple genomic alterations and provides key insi
Autor:
Lei Zhong, Gerald Li, Kimberly McGregor, Akshay Swaminathan, Tamara Snow, Samantha Morley, Margaret Elizabeth McCusker, Hanna Tukachinsky, Ole Gjoerup, Leah Comment, Alexa B. Schrock, Ryon Graf, Cheryl D. Cho-Phan, Sunandini Chopra, Virginia Fisher, Jeffrey S. Ross, Jeffrey M. Venstrom, Russell Madison, Amado J. Zurita
Publikováno v:
Journal of Clinical Oncology. 39:142-142
142 Background: Robust biomarkers for personalization of NHT treatment decisions remains an unmet need. Most assessments of candidate biomarkers to predict NHT resistance have been conducted in clinical trials or academic centers, meriting additional
Autor:
Iona Cheng, Shih-Wen Lin, Manali I. Patel, Juan Yang, Scarlett Lin Gomez, Heather A. Wakelee, Christina A. Clarke, Margaret Elizabeth McCusker, Alan B. Sandler
Publikováno v:
Journal of Global Oncology
Purpose Despite being the leading cause of cancer death, no prior studies have characterized survival patterns among Chinese Americans diagnosed with lung cancer. This study was conducted to identify factors associated with survival after lung cancer
Autor:
Tamara Snow, Emily Castellanos, Margaret Elizabeth McCusker, Brian M. Alexander, Alexa B. Schrock, Gaurav Singal, Gerald Li, Jeremy Snider, Akshay Swaminathan
Publikováno v:
Journal of Clinical Oncology. 38:3060-3060
3060 Background: The first tumor-agnostic, biomarker-based FDA approval in oncology was P in May 2017 for pts with MSI-H or mismatch repair (MMR) deficient tumors. 1 yr overall survival (OS) was >70% for colorectal cancer (CRC) and >60% for non-CRC i
Autor:
Tamara Snow, Emily Castellanos, Emmanuel S. Antonarakis, Margaret Elizabeth McCusker, Jeremy Snider, Alexa B. Schrock, Brian M. Alexander, Russell Madison, Jon Chung, Jeffrey M. Venstrom, Ethan Sokol, Jeffrey S. Ross, Gaurav Singal
Publikováno v:
Journal of Clinical Oncology. 38:5527-5527
5527 Background: Inactivating alts in BRCA1/2 result in homologous recombination deficiency and are predictive of PARPi response in mCRPC. BRCA reversion mutations, which restore the protein function, are frequently observed in acquired resistance to